The current price of UFPT is $301.79 — it has increased by 0.66% since the previous close. Data as of Nov 6, 2026.
UFPT is up 4.23% over the past week, down 0.26% over the past month and up 35.60% over the past year. The price is above its 200-day moving average of $250.00.
Analysts' average 12-month price target for UFPT is $298.00, which implies 1.26% downside from the current price. Individual estimates range from $252.00 to $344.00.
Of the 4 analysts covering UFP Technologies, Inc., 1 rates it a strong buy, 1 rates it a buy and 2 rate it a hold. The overall consensus is neutral. Analyst ratings are opinions and do not guarantee future performance.
UFP Technologies, Inc. has a market capitalization of $2.34B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, UFP Technologies, Inc. posted earnings of $2.88 per share against an estimate of $2.49, beating expectations by 15.66%. Upcoming reports are listed in the earnings calendar.
UFP Technologies, Inc. reported revenue of $172.43M in its most recent quarter, which has increased by 11.57% compared with the same quarter a year earlier. Analysts had expected $166.89M.
UFP Technologies, Inc. has not paid any dividends over the past year.
Companies most comparable to UFP Technologies, Inc. include Medtronic Plc, GE HealthCare Technologies Inc., Establishment Labs Holdings Inc., Enovis Corporation and CONMED Corporation.
In the latest trading session UFPT moved between $293.81 and $306.19, a range of 4.10% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of UFP Technologies, Inc. shows a strong buy rating today. Technical ratings are indicators, not investment advice.
Over the past 52 weeks UFPT has traded between $173.86 and $342.11. The current price is 11.79% below its 52-week high.
Figures as of Nov 6, 2026. This information is provided for general purposes only and is not investment advice.